Using new biological understanding to improve our ability to make better medicines
Kymab was founded through a vision and a technology that could dramatically accelerate both the speed of antibody drug development and improve the quality of antibody medicines. We believe that continued creative innovation is essential to maintaining our leading position and creating unique opportunities.
We are in a uniquely fertile time for genetic discovery and we are alert to new drug targets and the application of genetic knowledge in clinical development. Our ambition is to strengthen our innovative culture, recognising the long-term competitive advantage and value this brings.
Our IntelliSelect™ system captures and enables us to analyse the vast array of antibodies from Kymab’s platforms
Improving the performance and adaptability of our antibody platforms to enhance their ability to deliver candidate antibodies
With our effective platforms, we have a unique opportunity to generate innovative, high-value bispecific molecules
Identifying, testing and developing effective vaccines using our antibody platforms as a surrogate human immune system